Prostate cancer–specific PET radiotracers: A review on the clinical utility in recurrent disease
Tóm tắt
Từ khóa
Tài liệu tham khảo
Cooperberg, 2015, Trends in management for patients with localized prostate cancer, 1990-2013, JAMA, 314, 80, 10.1001/jama.2015.6036
Dale, 2005, The role of anxiety in prostate carcinoma: A structured review of the literature, Cancer, 104, 467, 10.1002/cncr.21198
Lofters, 2002, “PSA-itis:" Knowledge of serum prostate specific antigen and other causes of anxiety in men with metastatic prostate cancer, J Urol, 168, 2516, 10.1016/S0022-5347(05)64180-8
Clark, 2006, Confidence and uncertainty long after initial treatment for early prostate cancer: Survivors' views of cancer control and the treatment decisions they made, J Clin Oncol, 24, 4457, 10.1200/JCO.2006.06.2893
Sobol, 2017, Contemporary mapping of post-prostatectomy prostate cancer relapse with 11C-choline positron emission tomography and multiparametric magnetic resonance imaging, J Urol, 197, 129, 10.1016/j.juro.2016.07.073
Parker, 2017, Identification of site-specific recurrence following primary radiation therapy for prostate cancer using C-11 choline positron emission tomography/computed tomography: A nomogram for predicting extrapelvic disease, Eur Urol, 71, 340, 10.1016/j.eururo.2016.08.055
Parker, 2017, Patterns of recurrence after postprostatectomy fossa radiation therapy identified by c-11 choline positron emission tomography/computed tomography, Int J Radiat Oncol Biol Phys, 97, 526, 10.1016/j.ijrobp.2016.11.014
Evangelista, 2016, New clinical indications for (18)F/(11)C-choline, new tracers for positron emission tomography and a promising hybrid device for prostate cancer staging: A systematic review of the literature, Eur Urol, 70, 161, 10.1016/j.eururo.2016.01.029
Perera, 2016, Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: A systematic review and meta-analysis, Eur Urol, 70, 926, 10.1016/j.eururo.2016.06.021
Ost, 2015, Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: A systematic review of the literature, Eur Urol, 67, 852, 10.1016/j.eururo.2014.09.004
Supiot, 2015, OLIGOPELVIS - GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer, BMC Cancer, 15, 646, 10.1186/s12885-015-1579-0
Mohsen, 2013, Application of C-11-acetate positron-emission tomography (PET) imaging in prostate cancer: Systematic review and meta-analysis of the literature, BJU Int, 112, 1062, 10.1111/bju.12279
O'Doherty, 2017, Effect of Bayesian-penalized likelihood reconstruction on [13N]-NH3 rest perfusion quantification, J Nucl Cardiol, 24, 282, 10.1007/s12350-016-0554-8
Ross SQ. Clear White Paper. 2014; Available from: http://www3.gehealthcare.com/sitecore%20modules/web/~/media/downloads/italy/ge-healthcare-white-paper_qclear.pdf.
Cherry, 2001, Fundamentals of positron emission tomography and applications in preclinical drug development, J Clin Pharmacol, 41, 482, 10.1177/00912700122010357
Ackerstaff, 2001, Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells, Cancer Res, 61, 3599
Hernandez-Alcoceba, 1997, Choline kinase inhibitors as a novel approach for antiproliferative drug design, Oncogene, 15, 2289, 10.1038/sj.onc.1201414
Katz-Brull, 1996, Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method, Anticancer Res, 16, 1375
Janardhan, 2006, Choline kinase: An important target for cancer, Curr Med Chem, 13, 1169, 10.2174/092986706776360923
Robert, 2011, Metabolomics: A novel approach to early and noninvasive prostate cancer detection, Korean J Urol, 52, 79, 10.4111/kju.2011.52.2.79
Lima, 2016, Biomarker discovery in human prostate cancer: An update in metabolomics studies, Transl Oncol, 9, 357, 10.1016/j.tranon.2016.05.004
Awwad, 2012, The role of choline in prostate cancer, Clin Biochem, 45, 1548, 10.1016/j.clinbiochem.2012.08.012
Muller, 2009, Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment, Eur J Nucl Med Mol Imaging, 36, 1434, 10.1007/s00259-009-1117-x
Lodi, 2011, Magnetic resonance spectroscopy detectable metabolomic fingerprint of response to antineoplastic treatment, PLoS One, 6, e26155, 10.1371/journal.pone.0026155
Leek, 1995, Prostate-specific membrane antigen: Evidence for the existence of a second related human gene, Br J Cancer, 72, 583, 10.1038/bjc.1995.377
Maurer, 2016, Current use of PSMA-PET in prostate cancer management, Nat Rev Urol, 13, 226, 10.1038/nrurol.2016.26
Birtle, 2005, Tumour markers for managing men who present with metastatic prostate cancer and serum prostate-specific antigen levels of <10 ng/mL, BJU Int, 96, 303, 10.1111/j.1464-410X.2005.05619.x
Evans, 2011, Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen, Proc Natl Acad Sci U S A, 108, 9578, 10.1073/pnas.1106383108
Silver, 1997, Prostate-specific membrane antigen expression in normal and malignant human tissues, Clin Cancer Res, 3, 81
Bostwick, 1998, Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases, Cancer, 82, 2256, 10.1002/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S
Eder, 2012, 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging, Bioconjug Chem, 23, 688, 10.1021/bc200279b
Foss, 2005, Radiolabeled small-molecule ligands for prostate-specific membrane antigen: In vivo imaging in experimental models of prostate cancer, Clin Cancer Res, 11, 4022, 10.1158/1078-0432.CCR-04-2690
Cho, 2012, Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer, J Nucl Med, 53, 1883, 10.2967/jnumed.112.104661
Szabo, 2015, Initial evaluation of [(18)F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer, Mol Imaging Biol, 17, 565, 10.1007/s11307-015-0850-8
Rowe, 2016, PSMA-based [(18)F]DCFPyL PET/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer, Mol Imaging Biol, 18, 411, 10.1007/s11307-016-0957-6
Kelly, 2017, Synthesis and pre-clinical evaluation of a new class of high-affinity 18F-labeled PSMA ligands for detection of prostate cancer by PET imaging, Eur J Nucl Med Mol Imaging, 44, 647, 10.1007/s00259-016-3556-5
Dietlein, 2015, Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in patients with relapsed prostate cancer, Mol Imaging Biol, 17, 575, 10.1007/s11307-015-0866-0
Cardinale, 2017, Preclinical evaluation of 18F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging, J Nucl Med, 58, 425, 10.2967/jnumed.116.181768
Harada, 2016, Synthesis and biologic evaluation of novel 18f-labeled probes targeting prostate-specific membrane antigen for PET of prostate cancer, J Nucl Med, 57, 1978, 10.2967/jnumed.116.175810
Bouvet, 2016, Automated synthesis of [(18)F]DCFPyL via direct radiofluorination and validation in preclinical prostate cancer models, EJNMMI Res, 6, 40, 10.1186/s13550-016-0195-6
Budaus, 2016, Initial experience of (68)Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy, Eur Urol, 69, 393, 10.1016/j.eururo.2015.06.010
Pfob, 2016, Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer, Eur J Nucl Med Mol Imaging, 43, 1962, 10.1007/s00259-016-3424-3
Afshar-Oromieh, 2016, Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing, Eur J Nucl Med Mol Imaging, 43, 1611, 10.1007/s00259-016-3419-0
Oka, 2007, A preliminary study of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer, J Nucl Med, 48, 46
Sasajima, 2013, Trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid (anti-18F-FACBC) is a feasible alternative to 11C-methyl-L-methionine and magnetic resonance imaging for monitoring treatment response in gliomas, Nucl Med Biol, 40, 808, 10.1016/j.nucmedbio.2013.04.007
Oka, 2012, Transport mechanisms of trans-1-amino-3-fluoro[1-(14)C]cyclobutanecarboxylic acid in prostate cancer cells, Nucl Med Biol, 39, 109, 10.1016/j.nucmedbio.2011.06.008
Schuster, 2016, PET tracers beyond FDG in prostate cancer, Semin Nucl Med, 46, 507, 10.1053/j.semnuclmed.2016.07.005
Savir-Baruch, 2017, Imaging of prostate cancer using fluciclovine, PET Clin, 12, 145, 10.1016/j.cpet.2016.11.005
Ganapathy, 2009, Nutrient transporters in cancer: Relevance to Warburg hypothesis and beyond, Pharmacol Ther, 121, 29, 10.1016/j.pharmthera.2008.09.005
Nakanishi, 2011, Solute carrier transporters as targets for drug delivery and pharmacological intervention for chemotherapy, J Pharm Sci, 100, 3731, 10.1002/jps.22576
Oka, 2014, Differences in transport mechanisms of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid in inflammation, prostate cancer, and glioma cells: Comparison with L-[methyl-11C]methionine and 2-deoxy-2-[18F]fluoro-D-glucose, Mol Imaging Biol, 16, 322, 10.1007/s11307-013-0693-0
Asano, 2011, Phase I clinical study of NMK36: A new PET tracer with the synthetic amino acid analogue anti-[18F]FACBC, Ann Nucl Med, 25, 414, 10.1007/s12149-011-0477-z
Spratt, 2014, Utility of FDG-PET in clinical neuroendocrine prostate cancer, Prostate, 74, 1153, 10.1002/pros.22831
Fanti, 2016, PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: Meta-analysis and critical review of available data, Eur J Nucl Med Mol Imaging, 43, 55, 10.1007/s00259-015-3202-7
Evangelista, 2013, Choline PET or PET/CT and biochemical relapse of prostate cancer: A systematic review and meta-analysis, Clin Nucl Med, 38, 305, 10.1097/RLU.0b013e3182867f3c
Umbehr, 2013, The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: A systematic review and meta-analysis, Eur Urol, 64, 106, 10.1016/j.eururo.2013.04.019
Shen, 2014, Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: A meta-analysis, Skelet Radiol, 43, 1503, 10.1007/s00256-014-1903-9
Kitajima, 2014, Detection of recurrent prostate cancer after radical prostatectomy: Comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil, J Nucl Med, 55, 223, 10.2967/jnumed.113.123018
Ren, 2016, The value of anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT in the diagnosis of recurrent prostate carcinoma: A meta-analysis, Acta Radiol, 57, 487, 10.1177/0284185115581541
Schuster, 2014, Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: Results of a prospective clinical trial, J Urol, 191, 1446, 10.1016/j.juro.2013.10.065
Odewole, 2016, Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: Comparison with CT, Eur J Nucl Med Mol Imaging, 43, 1773, 10.1007/s00259-016-3383-8
Mitchell, 2013, Operational characteristics of (11)c-choline positron emission tomography/computerized tomography for prostate cancer with biochemical recurrence after initial treatment, J Urol, 189, 1308, 10.1016/j.juro.2012.10.069
Nanni, 2016, (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: Results of a prospective trial, Eur J Nucl Med Mol Imaging, 43, 1601, 10.1007/s00259-016-3329-1
Morigi, 2015, Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy, J Nucl Med, 561185
Afshar-Oromieh, 2014, Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer, Eur J Nucl Med Mol Imaging, 41, 11, 10.1007/s00259-013-2525-5
Schwenck, 2017, Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT, Eur J Nucl Med Mol Imaging, 44, 92, 10.1007/s00259-016-3490-6
Nanni, 2015, 18F-fluciclovine PET/CT for the detection of prostate cancer relapse: A comparison to 11C-choline PET/CT, Clin Nucl Med, 40, e386, 10.1097/RLU.0000000000000849
Nanni, 2014, 18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: A prospective study in 28 patients, Clin Genitourin Cancer, 12, 106, 10.1016/j.clgc.2013.08.002
Nanni, 2013, Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results, Eur J Nucl Med Mol Imaging, 40, S11, 10.1007/s00259-013-2373-3
2012, J Nucl Med, 53, 11N
Taneja, 2004, Imaging in the diagnosis and management of prostate cancer, Rev Urol, 6, 101
Abuzallouf, 2004, Baseline staging of newly diagnosed prostate cancer: A summary of the literature, J Urol, 171, 2122, 10.1097/01.ju.0000123981.03084.06
Albertsen, 2000, The positive yield of imaging studies in the evaluation of men with newly diagnosed prostate cancer: A population based analysis, J Urol, 163, 1138, 10.1016/S0022-5347(05)67710-5
Cooperberg, 2002, Contemporary trends in imaging test utilization for prostate cancer staging: Data from the cancer of the prostate strategic urologic research endeavor, J Urol, 168, 491, 10.1016/S0022-5347(05)64665-4
Tendulkar, 2016, Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy, J Clin Oncol, 10.1200/JCO.2016.67.9647
Stish, 2016, Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer, J Clin Oncol, 10.1200/JCO.2016.68.3425
Giovacchini, 2010, Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy, Eur J Nucl Med Mol Imaging, 37, 301, 10.1007/s00259-009-1253-3
Richter, 2010, Dual tracer 11C-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment, Mol Imaging Biol, 12, 210, 10.1007/s11307-009-0243-y
Krause, 2008, The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer, Eur J Nucl Med Mol Imaging, 35, 18, 10.1007/s00259-007-0581-4
Castellucci, 2009, Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy, J Nucl Med, 50, 1394, 10.2967/jnumed.108.061507
Cimitan, 2015, Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: Experience with 1,000 patients, J Nucl Med, 56, 209, 10.2967/jnumed.114.141887
Schillaci, 2012, Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy, Eur J Nucl Med Mol Imaging, 39, 589, 10.1007/s00259-011-2030-7
Afshar-Oromieh, 2015, The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer, Eur J Nucl Med Mol Imaging, 42, 197, 10.1007/s00259-014-2949-6
Eiber, 2015, Evaluation of hybrid (6)(8)Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy, J Nucl Med, 56, 668, 10.2967/jnumed.115.154153
Bluemel, 2016, 68Ga-PSMA-PET/CT in patients with biochemical prostate cancer recurrence and negative 18F-choline-PET/CT, Clin Nucl Med, 41, 515, 10.1097/RLU.0000000000001197
Verburg, 2016, Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score, Eur J Nucl Med Mol Imaging, 43, 397, 10.1007/s00259-015-3240-1